Last reviewed · How we verify
Cognitive Remediation — Competitive Intelligence Brief
phase 3
Psychiatry/Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cognitive Remediation (Cognitive Remediation) — New York State Psychiatric Institute. Cognitive Remediation is a behavioral intervention that uses structured training and practice to improve cognitive functions such as attention, memory, and executive function in patients with psychiatric or neurological disorders.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cognitive Remediation TARGET | Cognitive Remediation | New York State Psychiatric Institute | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cognitive Remediation CI watch — RSS
- Cognitive Remediation CI watch — Atom
- Cognitive Remediation CI watch — JSON
- Cognitive Remediation alone — RSS
Cite this brief
Drug Landscape (2026). Cognitive Remediation — Competitive Intelligence Brief. https://druglandscape.com/ci/cognitive-remediation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing